These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37194136)

  • 1. Point-Counterpoint: Staging Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Detecting Clinically Node Positive Prostate Cancer.
    Andrews JR; Sood A; Chapin BF
    J Urol; 2023 Aug; 210(2):242-243. PubMed ID: 37194136
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer.
    van Kalmthout LWM; van Melick HHE; Lavalaye J; Meijer RP; Kooistra A; de Klerk JMH; Braat AJAT; Kaldeway HP; de Bruin PC; de Keizer B; Lam MGEH
    J Urol; 2020 Mar; 203(3):537-545. PubMed ID: 31487220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate Specific Membrane Antigen Targeted
    Gorin MA; Rowe SP; Patel HD; Vidal I; Mana-Ay M; Javadi MS; Solnes LB; Ross AE; Schaeffer EM; Bivalacqua TJ; Partin AW; Pienta KJ; Szabo Z; De Marzo AM; Pomper MG; Allaf ME
    J Urol; 2018 Jan; 199(1):126-132. PubMed ID: 28736318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal Timing of Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Biochemical Recurrence after Radical Prostatectomy.
    Luiting HB; van Leeuwen PJ; Remmers S; Donswijk M; Busstra MB; Bakker IL; Brabander T; Stokkel M; van der Poel HG; Roobol MJ
    J Urol; 2020 Sep; 204(3):503-510. PubMed ID: 32149575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate Cancer: Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography or Positron-emission Tomography/Magnetic Resonance Imaging for Staging.
    Ferraro DA; Burger IA
    Top Magn Reson Imaging; 2020 Feb; 29(1):59-66. PubMed ID: 32015295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific Membrane Antigen Positron Emission Tomography in the Staging of Newly Diagnosed Prostate Cancer: Is More Sensitivity Always Better?
    Varatharajan A; Olivier T; Prasad V
    Eur Urol; 2023 Jun; 83(6):481-483. PubMed ID: 36774222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with
    Pienta KJ; Gorin MA; Rowe SP; Carroll PR; Pouliot F; Probst S; Saperstein L; Preston MA; Alva AS; Patnaik A; Durack JC; Stambler N; Lin T; Jensen J; Wong V; Siegel BA; Morris MJ
    J Urol; 2021 Jul; 206(1):52-61. PubMed ID: 33634707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific membrane antigen positron emission tomography/computed tomography funding grants free access to superior staging for Australian men with prostate cancer.
    O'Brien JS; McVey A; Kelly BD; Jenjitranant P; Buteau J; Hofman MS; Kasivisvanithan V; Eapen R; Moon D; Murphy DG; Lawrentschuk N
    BJU Int; 2022 Nov; 130 Suppl 3():8-10. PubMed ID: 35574991
    [No Abstract]   [Full Text] [Related]  

  • 9. Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with
    Yaxley JW; Raveenthiran S; Nouhaud FX; Samartunga H; Yaxley AJ; Coughlin G; Delahunt B; Egevad L; McEwan L; Wong D
    J Urol; 2019 Apr; 201(4):815-820. PubMed ID: 30672842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
    Lenis AT; Pooli A; Lec PM; Sadun TY; Johnson DC; Lebacle C; Fendler WP; Eiber M; Czernin J; Reiter RE; Calais J
    Eur Urol Oncol; 2022 Oct; 5(5):544-552. PubMed ID: 32958451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prostate-specific membrane antigen positron emission tomography (PSMA PET) for urologists-when and which tracer?].
    Berliner C; Kesch C; Fendler WP; Eiber M; Maurer T
    Urologe A; 2022 Apr; 61(4):384-391. PubMed ID: 35138414
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of
    Fossati N; Scarcella S; Gandaglia G; Suardi N; Robesti D; Boeri L; Karnes RJ; Heidenreich A; Pfister D; Kretschmer A; Buchner A; Stief C; Battaglia A; Joniau S; Van Poppel H; Osmonov D; Juenemann KP; Shariat S; Hiester A; Nini A; Albers P; Tilki D; Graefen M; Gill IS; Mottrie A; Galosi AB; Montorsi F; Briganti A
    J Urol; 2020 Aug; 204(2):296-302. PubMed ID: 32068488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard.
    Stabile A; Pellegrino A; Mazzone E; Cannoletta D; de Angelis M; Barletta F; Scuderi S; Cucchiara V; Gandaglia G; Raggi D; Necchi A; Karakiewicz P; Montorsi F; Briganti A
    Eur Urol Oncol; 2022 Feb; 5(1):1-17. PubMed ID: 34538770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of metastatic disease on
    Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
    BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (
    Bach-Gansmo T; Nanni C; Nieh PT; Zanoni L; Bogsrud TV; Sletten H; Korsan KA; Kieboom J; Tade FI; Odewole O; Chau A; Ward P; Goodman MM; Fanti S; Schuster DM; Willoch F
    J Urol; 2017 Mar; 197(3 Pt 1):676-683. PubMed ID: 27746282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [
    Alemozaffar M; Akintayo AA; Abiodun-Ojo OA; Patil D; Saeed F; Huang Y; Osunkoya AO; Goodman MM; Sanda M; Schuster DM
    J Urol; 2020 Oct; 204(4):734-740. PubMed ID: 32347780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?
    Hussain M; Carducci MA; Clarke N; Fenton SE; Fizazi K; Gillessen S; Jacene H; Morris MJ; Saad F; Sartor O; Taplin ME; Vapiwala N; Williams S; Sweeney C
    J Clin Oncol; 2022 Sep; 40(26):3011-3014. PubMed ID: 35439030
    [No Abstract]   [Full Text] [Related]  

  • 19. Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis.
    Chow KM; So WZ; Lee HJ; Lee A; Yap DWT; Takwoingi Y; Tay KJ; Tuan J; Thang SP; Lam W; Yuen J; Lawrentschuk N; Hofman MS; Murphy DG; Chen K
    Eur Urol; 2023 Jul; 84(1):36-48. PubMed ID: 37032189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography for staging of high-risk prostate cancer.
    Petersen LJ; Zacho HD
    Scand J Urol; 2017 Dec; 51(6):498-501. PubMed ID: 28748722
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.